Heron Therapeutics’ (HRTX) “Buy” Rating Reiterated at Mizuho

Heron Therapeutics (NASDAQ:HRTX)‘s stock had its “buy” rating reaffirmed by investment analysts at Mizuho in a report issued on Tuesday. They presently have a $28.00 price target on the biotechnology company’s stock. Mizuho’s target price suggests a potential upside of 29.63% from the company’s current price.

HRTX has been the topic of a number of other reports. Oppenheimer initiated coverage on Heron Therapeutics in a research report on Monday, October 30th. They issued a “buy” rating and a $27.00 price target on the stock. Noble Financial reissued a “buy” rating on shares of Heron Therapeutics in a research report on Sunday, November 12th. Cantor Fitzgerald set a $31.00 price target on Heron Therapeutics and gave the stock a “buy” rating in a research report on Friday, October 20th. ValuEngine raised Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, November 30th. Finally, Cowen reissued a “buy” rating and issued a $40.00 price target on shares of Heron Therapeutics in a research report on Wednesday, December 6th. Three research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $28.82.

Heron Therapeutics (NASDAQ HRTX) traded up $0.20 during trading on Tuesday, reaching $21.60. The company’s stock had a trading volume of 695,422 shares, compared to its average volume of 1,079,933. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.02 and a current ratio of 2.12. The company has a market cap of $1,382.44, a PE ratio of -5.70 and a beta of 2.13. Heron Therapeutics has a fifty-two week low of $12.25 and a fifty-two week high of $22.00.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.77) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.87) by $0.10. The business had revenue of $8.57 million for the quarter, compared to analysts’ expectations of $8.12 million. Heron Therapeutics had a negative return on equity of 385.11% and a negative net margin of 831.89%. equities analysts forecast that Heron Therapeutics will post -3.38 EPS for the current year.

In other news, VP Kimberly Manhard sold 7,584 shares of the business’s stock in a transaction that occurred on Wednesday, January 10th. The stock was sold at an average price of $20.00, for a total value of $151,680.00. Following the sale, the vice president now directly owns 7,584 shares of the company’s stock, valued at approximately $151,680. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 19.93% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Janus Henderson Group PLC purchased a new position in Heron Therapeutics in the 2nd quarter worth approximately $78,134,000. Virtu KCG Holdings LLC raised its holdings in Heron Therapeutics by 62.5% in the 2nd quarter. Virtu KCG Holdings LLC now owns 25,053 shares of the biotechnology company’s stock worth $347,000 after acquiring an additional 9,637 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in Heron Therapeutics by 7.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 204,857 shares of the biotechnology company’s stock worth $2,837,000 after acquiring an additional 14,086 shares during the last quarter. C WorldWide Group Holding A S purchased a new position in Heron Therapeutics in the 3rd quarter worth approximately $1,615,000. Finally, Alyeska Investment Group L.P. raised its holdings in Heron Therapeutics by 9.5% in the 3rd quarter. Alyeska Investment Group L.P. now owns 754,657 shares of the biotechnology company’s stock worth $12,188,000 after acquiring an additional 65,260 shares during the last quarter. Institutional investors own 98.21% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Heron Therapeutics’ (HRTX) “Buy” Rating Reiterated at Mizuho” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/16/heron-therapeutics-hrtx-buy-rating-reiterated-at-mizuho.html.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply